Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Grows By 70.8%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 274,164 shares, a growth of 70.8% from the December 31st total of 160,518 shares. Based on an average trading volume of 1,037,269 shares, the days-to-cover ratio is presently 0.3 days. Currently, 19.6% of the shares of the company are sold short. Currently, 19.6% of the shares of the company are sold short. Based on an average trading volume of 1,037,269 shares, the days-to-cover ratio is presently 0.3 days.

Shuttle Pharmaceuticals Stock Performance

Shares of SHPH stock opened at $2.02 on Friday. Shuttle Pharmaceuticals has a 52-week low of $1.26 and a 52-week high of $19.95. The stock has a market cap of $3.23 million, a price-to-earnings ratio of -0.17 and a beta of -1.00. The firm has a fifty day moving average of $1.77 and a 200-day moving average of $2.88.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Shuttle Pharmaceuticals has an average rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned approximately 9.40% of Shuttle Pharmaceuticals at the end of the most recent reporting period. 4.58% of the stock is owned by hedge funds and other institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .